Skip to main content

Table 1 Patient demographics and baseline disease characteristics, safety population

From: Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin

 

G-GR 1800 mg/day

(n = 556)

Age (years)

 

 Mean (SD)

66.7 (12.9)

 Median

69.0

 Range

18–92

Age category, n (%)

 

  < 55 years

89 (16.0)

 55–64 years

109 (19.6)

 65–74 years

195 (35.1)

  ≥ 75 years

163 (29.3)

Sex, n (%)

 

 Male

221 (39.7)

 Female

335 (60.3)

Race, n (%)

 

 Caucasian

479 (86.2)

 African American

29 (5.2)

 Hispanic

38 (6.8)

 Other

10 (1.8)

Baseline VAS (mm)

 

 Mean (SD)

66.1 (56.9)

 Median

64.0

 Range

2–91

Baseline VAS category, n (%)

 

  ≤ 20 mm

15 (2.7)

  > 20 mm

531 (95.5)

Baseline BPI Sleep Interference by Pain

 

 Mean (SD)

5.1 (2.9)

 Median

5

 Range

0–10